Podcast Episodes
Back to Search
Ep. 108 - Rethinking Discovery: Chris Hollowood on Causal Biology and Syncona’s Strategy
Season 5 Episode 108
A paradigm shift in research tools, combined with large-scale unbiased screening, has positioned the biopharma industry not only to rethink target di…
4 months ago
Ep. 107 - Forbion’s Slootweg on Europe Biotech, NewCos From Asia and Green Investing
Season 5 Episode 107
The European biotech ecosystem has gone through a substantial maturation process over the past 20 years, as VC funds such as Forbion have experienced…
4 months, 2 weeks ago
Ep. 106 - Can the U.K. Capture Biotech Value? Daniel Mahony on Growth, Pricing and Reform
Season 5 Episode 106
The U.K. is excellent at invention and science, and creating institutions to further innovation, but poor at capturing their economic value, says Dan…
5 months ago
Ep. 105 - Recursion’s Najat Khan: AI Will Be Judged by the Medicines It Delivers
Season 5 Episode 105
As AI spreads across biopharma, what will matter most is not who has the flashiest tools, but who can use them to make better medicines. In this epis…
5 months, 2 weeks ago
Ep. 104 - SoftBank’s Jacqueline Fok on AI Drug Development, Metsera and the U.K. Biotech Opportunity
Season 5 Episode 104
There is a real opportunity for artificial intelligence to dramatically transform the speed, cost and efficiency of drug development over the long te…
5 months, 4 weeks ago
Ep. 103 - Kolchinsky: FDA Conservatism, MFN and IRA Are Slowing Drug Development
Season 5 Episode 103
Caution: This episode of The BioCentury Show contains strong language.
In a candid interview with BioCentury, RA Capital Managing Partner Peter Kolchi…
6 months, 2 weeks ago
Ep. 102 - Psychiatry R&D: Steve Paul on Serendipity, Engineering and What Drives Real Breakthroughs
Season 5 Episode 102
With disease biology still murky and trials notoriously noisy, psychiatry R&D is advancing fastest where teams can solve engineering problems. Delive…
6 months, 4 weeks ago
Ep. 101 - Why Science Stalls: Astellas CEO Naoki Okamura on Translation, Talent and Platforms
Season 5 Episode 101
Why does great science so often stall before it becomes a medicine? Astellas Pharma CEO Naoki Okamura argues the bottleneck isn’t capital — it’s tran…
7 months, 1 week ago
Ep. 100 - Adam Koppel on Why Private Equity Is Moving Deeper Into Biotech and What Comes Next
Season 5 Episode 100
Private equity’s expanding role in biopharma as a growth equity investor reflects both the maturation of the life sciences sector and the rising need…
7 months, 3 weeks ago
Ep. 99 – Stelios Papadopoulos on Biotech’s Long View: Pricing Pressure, China & Big Pharma
Season 4 Episode 99
In historical terms, this is not a bear market, says Stelios Papadopoulos. There’s volatility, which is unnerving, and major issues to reckon with, b…
8 months, 2 weeks ago